ReviewFrontiers in pharmacology2022
Ferroptosis: A new therapeutic target for bladder cancer.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- GLI2 confers ferroptosis resistance in bladder cancer by transcriptionally upregulating PRDX1.Apoptosis : an international journal on programmed cell death · 2026Article
- The Dual Role of Ferroptosis in Cancer: Molecular Mechanisms, Microenvironment Crosstalk, and Precision Therapeutics.Cancers · 2026Review
- Artesunate nanoliposomes in hepatocellular carcinoma: mechanistic ferroptosis induction and translational opportunities.Discover oncology · 2026Review
- A mitochondrial regulatory network of ferroptosis defense in HPV-positive cervical cancer: therapeutic implications of the mitoSTAT3-DHODH axis.Frontiers in pharmacology · 2026Review
- Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.Food science & nutrition · 2025Article
- miR-25-3p Modulates Tumor Aggressiveness and Ferroptosis Escape in T24 Bladder Cancer Cells In Vitro.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Tanshinone IIA induces ferroptosis in colorectal cancer cells through the suppression of SLC7A11 expression via the PI3K/AKT/mTOR pathway.European journal of medical research · 2025Article
- USP5 Suppresses Ferroptosis in Bladder Cancer Through Stabilization of GPX4.Current issues in molecular biology · 2025Article
- DDR1 Targeting HOXA6 Facilitates Bladder Cancer Progression via Inhibiting Ferroptosis.Journal of cellular and molecular medicine · 2025Article
- Methyltransferase-like 7B participates in bladder cancer via ACSL3 mBiology direct · 2025Article
- Ferroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities.Frontiers in immunology · 2025Review
- Silencing CCT3 induces ferroptosis through the NOD1-NF-κB signaling pathway in bladder cancer.Scientific reports · 2024Article
- Mechanisms of ferroptosis and targeted therapeutic approaches in urological malignancies.Cell death discovery · 2024Review
- Current and Potential Roles of Ferroptosis in Bladder Cancer.Current medical science · 2024Review
- Exploration of potential biomarkers for early bladder cancer based on urine proteomics.Frontiers in oncology · 2024Article
- Targeting ferroptosis, a novel programmed cell death, for the potential of alcohol-related liver disease therapy.Frontiers in pharmacology · 2023Review
- Study on the Role and Mechanism of SLC3A2 in Tumor-Associated Macrophage Polarization and Bladder Cancer Cells Growth.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is the most frequent type of urinary system cancer. The prognosis of BC is poor due to high metastasis rates and multidrug resistance. Hence, development of novel therapies targeting BC cell death is urgently needed. As a novel cell death type with strong antitumor potential, ferroptosis has been investigated by many groups for its potential in BC treatment. As an iron-dependent cell death process, ferroptosis is characterized by excessive oxidative phospholipids. The molecular mechanisms of ferroptosis include iron overload and the system Xc-GSH-GPX4 signaling pathway. A recent study revealed that ferroptosis is involved in the metastasis, treatment, and prognosis of BC. Herein, in this review, we comprehensively summarize the mechanism of ferroptosis, address newly identified targets involved in ferroptosis, and discuss the potential of new clinical therapies targeting ferroptosis in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.